Health
- Business
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Copenhagen, Denmark & Ingelheim, Germany: New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management…
Read More »